Rao L. Divi, Ph.D.
Program Director, Methods and Technologies Branch

Address:
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E118, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)

Interest Areas

  • Cancer risk and causal markers (molecular/cellular/tissue)
  • Non-invasive or minimally invasive modalities for assessing cancer risk and detecting cancer
  • Development and validation of cancer-relevant methods and technologies for cancer epidemiology
  • Affordable molecular and cellular technologies to address cancer health disparities
  • Information technology for analyzing, integrating, visualizing, and disseminating large-scale multilevel data
  • Bioinformatics
  • Global health technologies for cancer care continuum
  • Molecular and histopathology technologies for cancer risk, risk of metastasis, risk of recurrence, and survival assessment
  • Methods for risk prediction (both primary and metastasis)
  • High-throughput technologies for biological markers of exposure (diet/environment/drug)
  • Exposome
  • Co-infections and cancer
  • Cancer health disparities
  • Carcinoma of unknown primary
  • Autophagy
  • Immunogenomics
  • Physical technologies for sequencing nucleic acids
  • Mosaic gene-function analysis
  • Preneoplastic markers
  • Carcinogenesis
  • Environment/diet/drug toxicity and carcinogenicity
  • Gene-Environment Interactions
  • Circulating cell-free DNA, tumor DNA, exosomes and oncosomes

Degrees

  • Ph.D. - Biochemistry
    Osmania University
  • M.Sc. - Biochemistry
    Andhra University
  • B.Sc. - Organic Chemistry
    Andhra University

Biography

Dr. Divi is a Program Director in the Methods and Technologies Branch (MTB). His responsibilities include managing a research portfolio and initiatives that focus on the development of methods and technologies to address epidemiologic data collection, study design and analysis, and validation of emerging technologies for application across the cancer control continuum. He is the EGRP representative to the International Lymphoma Epidemiology Consortium (InterLymph); the Chronic Lymphocytic Leukemia Research Consortium (CRC); the Identification of Men with a Genetic Predisposition to ProstAte Cancer: Targeted screening in BRCA1 and BRCA2 mutation carriers and controls (IMPACT) Consortium; and the Prevention and Observation of Surgical Endpoints and Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (PROSE-Modifiers Studies) (Collaborative Studies of BRCA 1/2 Mutation Carriers) Consortium. Dr. Divi is also a member of the InterLymph Coordinating Committee.

He joined EGRP in 2008 from NCI's intramural Laboratory of Cancer Biology and Genetics. Since 1997, he had been a member of the Laboratory's Carcinogen-DNA Interactions Section, where he focused on understanding the genotoxicity and carcinogenicity of cisplatin, tamoxifen, PHIP, and polycyclic aromatic hydrocarbons, as well as the mitochondrial toxicity of antiretroviral drugs. A significant portion of Dr. Divi's work focused on identification of molecular markers, development of methods and technologies for the markers, and validation of those markers through intra- and interlaboratory collaborations. He used these molecular markers in collaborative studies that assessed risk in humans and animal models.

Prior to joining NCI, Dr. Divi worked for four years at the National Center for Toxicological Research, which is the research arm of the U.S. Food and Drug Administration (FDA), in Jefferson, AR. Here he conducted research on the antithyroid activity of drugs and environmental toxicants. He also worked for a year on an International Atomic Energy Agency project on health effects of trace elements.

Return to Top